FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4206998396> ?p ?o ?g. }

• W4206998396 abstract "Abstract Background A precise, simple, accurate, and quick HPLC–PDA method for the determination of eluxadoline and rifaximin in rat plasma was developed and validated in this study. In this method, Loperamide hydrochloride was used as the internal standard and plasma samples were prepared using a liquid–liquid extraction technique for which acetonitrile was a solvent. An Agilent Symmetry C8 column (5 µm, 250 mm × 4.6 mm) at 283 nm and isocratic elution using HPLC grade acetonitrile and 7 mM TEA (pH 2.5) with a ratio of (40: 60 v/v) was used as a mobile phase and the flow rate employed was 1 mL min −1 . A satisfactory chromatographic separation was accomplished. Results An HPLC–PDA method for the determination of eluxadoline and rifaximin with retention times of 3.06 and 7.82 min, respectively, was developed. The calibration curves appear linear for both eluxadoline and rifaximin in the range of 5–200 ng mL −1 and 10–400 ng mL −1 , and the corresponding correlation coefficient values were found to be 0.9999 and 0.9998 respectively. Lower limits of quantification (LLOQ) for eluxadoline and rifaximin were evaluated to be 5.0 ng mL −1 and 10.0 ng mL −1 , respectively. The accuracy and precision results in all validation experiments were within the acceptance limits of FDA guidelines. Conclusion The developed HPLC–PDA approach was fully validated to meet the USFDA guidelines for bioanalytical method validation in terms of precision, accuracy, and stability. The presented approach could be beneficial for the determination of ELX and RFX in rat plasma, according to validation parameters. This is one of the efficient method to study the pharmacokinetics of ELX and RFX in rats. Graphical abstract" @default.
• W4206998396 created "2022-01-26" @default.
• W4206998396 creator A5065202516 @default.
• W4206998396 creator A5079606365 @default.
• W4206998396 creator A5080925030 @default.
• W4206998396 creator A5087129772 @default.
• W4206998396 date "2022-01-25" @default.
• W4206998396 modified "2023-10-14" @default.
• W4206998396 title "Validation of the HPLC–PDA method for detection of eluxadoline and rifaximin in rat plasma and application in a pharmacokinetic study" @default.
• W4206998396 cites W1548949496 @default.
• W4206998396 cites W2053455313 @default.
• W4206998396 cites W2060038902 @default.
• W4206998396 cites W2065530845 @default.
• W4206998396 cites W2067719457 @default.
• W4206998396 cites W2139802092 @default.
• W4206998396 cites W2162967567 @default.
• W4206998396 cites W2330377679 @default.
• W4206998396 cites W2522212374 @default.
• W4206998396 cites W2758946513 @default.
• W4206998396 cites W2765675226 @default.
• W4206998396 cites W2901658210 @default.
• W4206998396 cites W2910790685 @default.
• W4206998396 cites W2939165344 @default.
• W4206998396 cites W2964979565 @default.
• W4206998396 cites W3009509257 @default.
• W4206998396 cites W3023535500 @default.
• W4206998396 cites W3127304929 @default.
• W4206998396 cites W3133397015 @default.
• W4206998396 cites W3164445153 @default.
• W4206998396 cites W2371518627 @default.
• W4206998396 doi "https://doi.org/10.1186/s43094-022-00403-x" @default.
• W4206998396 hasPublicationYear "2022" @default.
• W4206998396 type Work @default.
• W4206998396 citedByCount "1" @default.
• W4206998396 countsByYear W42069983962023 @default.
• W4206998396 crossrefType "journal-article" @default.
• W4206998396 hasAuthorship W4206998396A5065202516 @default.
• W4206998396 hasAuthorship W4206998396A5079606365 @default.
• W4206998396 hasAuthorship W4206998396A5080925030 @default.
• W4206998396 hasAuthorship W4206998396A5087129772 @default.
• W4206998396 hasBestOaLocation W42069983961 @default.
• W4206998396 hasConcept C119128265 @default.
• W4206998396 hasConcept C137535248 @default.
• W4206998396 hasConcept C179998833 @default.
• W4206998396 hasConcept C185592680 @default.
• W4206998396 hasConcept C2777463227 @default.
• W4206998396 hasConcept C2778889925 @default.
• W4206998396 hasConcept C43617362 @default.
• W4206998396 hasConcept C501593827 @default.
• W4206998396 hasConcept C55493867 @default.
• W4206998396 hasConceptScore W4206998396C119128265 @default.
• W4206998396 hasConceptScore W4206998396C137535248 @default.
• W4206998396 hasConceptScore W4206998396C179998833 @default.
• W4206998396 hasConceptScore W4206998396C185592680 @default.
• W4206998396 hasConceptScore W4206998396C2777463227 @default.
• W4206998396 hasConceptScore W4206998396C2778889925 @default.
• W4206998396 hasConceptScore W4206998396C43617362 @default.
• W4206998396 hasConceptScore W4206998396C501593827 @default.
• W4206998396 hasConceptScore W4206998396C55493867 @default.
• W4206998396 hasFunder F4320317507 @default.
• W4206998396 hasFunder F4320334771 @default.
• W4206998396 hasIssue "1" @default.
• W4206998396 hasLocation W42069983961 @default.
• W4206998396 hasLocation W42069983962 @default.
• W4206998396 hasOpenAccess W4206998396 @default.
• W4206998396 hasPrimaryLocation W42069983961 @default.
• W4206998396 hasRelatedWork W1603333022 @default.
• W4206998396 hasRelatedWork W1964259887 @default.
• W4206998396 hasRelatedWork W1979512650 @default.
• W4206998396 hasRelatedWork W1998279148 @default.
• W4206998396 hasRelatedWork W2013299392 @default.
• W4206998396 hasRelatedWork W2032191029 @default.
• W4206998396 hasRelatedWork W2084062459 @default.
• W4206998396 hasRelatedWork W2096641431 @default.
• W4206998396 hasRelatedWork W2119552130 @default.
• W4206998396 hasRelatedWork W2155596957 @default.
• W4206998396 hasVolume "8" @default.
• W4206998396 isParatext "false" @default.
• W4206998396 isRetracted "false" @default.
• W4206998396 workType "article" @default.